Analysts Set Expectations for Vaxcyte FY2026 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Vaxcyte in a report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould anticipates that the company will post earnings of ($5.62) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share.

PCVX has been the topic of several other reports. Guggenheim reissued a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America dropped their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Price Performance

NASDAQ:PCVX traded up $0.10 on Wednesday, hitting $34.56. 1,186,805 shares of the company's stock were exchanged, compared to its average volume of 1,449,107. The firm has a 50-day moving average price of $32.67 and a 200-day moving average price of $63.03. Vaxcyte has a 52 week low of $27.66 and a 52 week high of $121.06. The company has a market cap of $4.46 billion, a P/E ratio of -7.51 and a beta of 1.20.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the company earned ($0.85) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PCVX. Allspring Global Investments Holdings LLC grew its stake in Vaxcyte by 70.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after buying an additional 246,049 shares during the last quarter. Blue Trust Inc. grew its position in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Rhumbline Advisers grew its position in shares of Vaxcyte by 4.7% during the 4th quarter. Rhumbline Advisers now owns 171,814 shares of the company's stock worth $14,065,000 after purchasing an additional 7,711 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in shares of Vaxcyte by 13.7% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 44,901 shares of the company's stock worth $3,676,000 after purchasing an additional 5,427 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Vaxcyte by 486.2% during the 4th quarter. Principal Financial Group Inc. now owns 308,939 shares of the company's stock worth $25,290,000 after purchasing an additional 256,237 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.